Viventia Bio Inc.

Viventia Biotechnologies Inc.

Arjune Premsukh

Jeannick Cizeau

Glen MacDonald

Joycelyn Entwistle

Shilpa Chooniedass

The present disclosure is related to compositions of antibodies and immunoconjugates that potentially lack T-cell epitopes and elicit reduced immune response. The antibody may be an antibody fragment, such as Fab, Fab', F(ab&#x2032;)2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments, multimers, and any combination thereof. In a further embodiment, the antibody may bind to an antigen epithelial cell adhesion molecule (EpCAM). In another embodiment, an immunoconjugate may comprise an antibody attached to an effector molecule, wherein the effector molecule may be a radioisotope, an antineoplastic agent, an immunomodulator, a biological response modifier, lectin, a toxin, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof.

Anti-EPCAM antibodies and methods of use

An optimized nucleic acid sequence encoding the immunoconjugate VB4-845 is disclosed. Modifications to the original VB4-845 nucleic acid sequence include optimization of the sequences encoding the Vregion, Vregion, linkers and pseudomonas exotoxin A. The modifications improved the yield of VB4-845 in anexpression system.

Growing community of inventors

Winnipeg, Canada

Arjune Premsukh